Evidence map›Paper›PMID 38260290›Full record

ArticleResearch square2024

Higher Inflammatory Response in Hepatocellular Carcinoma is Associated with Immune Cell Infiltration and a Better Outcome.

Masanori Oshi, Kohei Chida, Arya Mariam Roy, Gabriella Kim Mann, Nan An, Li Yan, Itaru Endo, Kazuaki Takabe

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Masanori OshiRoswell Park Comprehensive Cancer Center.
Kohei ChidaRoswell Park Comprehensive Cancer Center.
Arya Mariam RoyRoswell Park Comprehensive Cancer Center.
Gabriella Kim MannRoswell Park Comprehensive Cancer Center.
Nan AnRoswell Park Comprehensive Cancer Center.
Li YanRoswell Park Comprehensive Cancer Center.
Itaru EndoYokohama City University: Yokohama Shiritsu Daigaku.
Kazuaki TakabeRoswell Park Comprehensive Cancer Center.ORCID 0000-0002-6435-4241
Roswell Park Comprehensive Cancer Center · USYokohama City University · JP

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI CANDACE S JOHNSON · 1985 to 2026
$116.6M
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor ImmunityR01CA250412 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ABRAMS, SCOTT I., EVANS, SHARON S · 2021 to 2025
$3.4M
Leveraging the GTP Biosynthetic Pathway for Anti-Tumor TherapiesR37CA248018 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Anna Bianchi-Smiraglia · 2021 to 2026
$2.3M
Sphingosine-1 Phosphate in Breast Cancer Progression and LymphangiogenesisR01CA160688 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI TAKABE, KAZUAKI · 2012 to 2016
$1.5M
NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA160688NCI NIH HHS R01 CA250412NCI NIH HHS R37 CA248018
6 · The paper itself

Abstract

Background & Aims: Hepatocellular carcinoma (HCC) often develops from chronic liver inflammation. Inflammation within a tumor can either promote cancer progression or activate an immune response against it. This study aims to determine the clinical significance of enhanced inflammation in HCC. Methods: Data from 655 HCC patients across four cohorts (TCGA, GSE6764, GSE76427, GSE89377) were examined. Inflammatory response was quantified using a scoring system derived from the gene set variation analysis of the "INFLAMMATORY_RESPONSE" gene set. Results: A stepwise increase in inflammatory response was noted from normal liver to cirrhosis, with consistently lower levels in HCC across both GSE6764 and GSE89377 cohorts (both Conclusion: HCC with higher levels of inflammatory response demonstrated increased immune cell infiltration, enhanced immune-related and other pro-cancerous-related signaling, and better patient prognosis.

Indexed as

BiomarkerCarcinogenesisHepatocellular CarcinomaInflammatory

Identifiers

PMID38260290
PMCPMC10802714
OpenAlexW4390536290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.